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is a genetically mediated disease. The advent of clinical
genetic testing for ARVC now allows the identiﬁcation of
causal genetic mutations in up to 50% of patients (1).
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012; revised manuscript received April 3, 2013,ARVC (2) include a pathogenic mutation as a major crite-
rion for the diagnosis. After the identiﬁcation of a culprit
gene in an index patient, current guidelines recommend
genetic screening of family members, who are typically
asymptomatic of the disease (1,3).
The management of asymptomatic patients with ARVC
mutations can be challenging: clinical penetrance of the
disease is highly variable, and many gene carriers enjoy
active lifestyles and normal life spans. Of concern, however,
is that the earliest “latent” stage of ARVC is charac-
terized by normal electrocardiographic (ECG) ﬁndings with
undetectable structural heart disease but a risk for sudden
cardiac death that may be highest during exercise (4).
Therefore, testing that is able to identify a developing elec-
trical substrate for ventricular arrhythmia in asymptomatic,
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1773genotype-positive individuals may be beneﬁcial in guiding
exercise prescription and medical surveillance.
We hypothesized that exercise testing might be used to
expose a latent electrical substrate of ARVC in asymp-
tomatic gene carriers with resting ECG results absent of
major criteria for the disease. In the ﬁrst phase of this
study, we sought to identify and evaluate the frequency of
electrical abnormalities induced on exercise treadmill
testing (ETT) in asymptomatic patients with ARVC
mutations compared with healthy age-matched and sex-
matched controls. In phase 2 of this study, we expanded
our testing cohorts and also assessed whether identiﬁed
exercise abnormalities in asymptomatic gene carriers may
correlate with arrhythmia risk by evaluating the results of
ETT in a cohort of patients with ARVC with histories of
sustained ventricular arrhythmia or cardiac arrest.
Methods
Asymptomatic patients with ARVC genotypes were iden-
tiﬁed from 3 inherited arrhythmia clinics after cascade family
genetic screening following the identiﬁcation of an affected
ARVC proband.
In the ﬁrst study phase, 60 subjects were compared. This
cohort consisted of 30 asymptomatic ARVC gene carriers
and 30 age-matched and sex-matched healthy subjects.
Each gene carrier harbored a pathogenic mutation
predicted to cause ARVC according to the TFC (2)
(Online Table 1). Asymptomatic gene carriers under-
went resting 12-lead electrocardiography, signal-averaged
electrocardiography, 24-h Holter monitoring, and
magnetic resonance imaging or echocardiography. By
study design, the resting electrocardiograms of all
asymptomatic ARVC gene carriers exhibited no major
criteria for ARVC per the TFC (2).
ETT was performed in all gene carriers and controls.
Abnormalities of depolarization and repolarization were
recorded. Depolarization abnormalities included new epsilon
waves in leads V1 and V2, premature ventricular contractions
(PVCs) categorized as superior or inferior or indetermi-
nate axis, and prolonged QRS terminal activation duration
(TAD) 55 ms in leads V1 and V2. Repolarization abnor-
malities analyzed included new T-wave inversion (TWI)
beyond lead V2 and new ST-segment elevation 0.1 mV in
either lead V1 or lead V2.
In phase 2 of the study, the ETT results of 25 patients
with ARVC and a history of sustained ventricular ar-
rhythmia and/or cardiac arrest were evaluated to deter-
mine the frequency of the ETT observations in this
cohort. In addition, we expanded our ETT observations in
asymptomatic ARVC gene carriers by 17 patients, for
a total of 47 patients, and evaluated the ETT results of an
additional 40 controls, for a total of 70 healthy individ-
uals, to more accurately determine the speciﬁcity of
exercise abnormalities identiﬁed in phase 1.Details of analyses and statis-
tical methods are available in the
Online Appendix.Results
ETT in asymptomatic ARVC
gene carriers andhealthy controls.
BASELINE CHARACTERISTICS. The
mean age of the asymptomatic
ARVC gene carrier cohort was
39.6  18.9 years, and the
mean age of the healthy control
group was 38.4  10.7 years
(p ¼ 0.80).
Of gene carriers, 27 of 30
(90%) harbored plakophilin-2
(PKP2) mutations (Table 1). The PKP2 mutations were
“radical” in 24 of 27 (90%). Digenic heterozygosity was
present in 2 subjects (#12 and #13). Both patients harbored
rare missense PKP2 and desmoglein 2 mutations. A single
subject (#14) was heterozygous for the Val56Met missense
mutation in desmoglein-2. This variant segregated with
2 affected family members, including an identical twin
diagnosed with ARVC at necropsy after sudden death.
This variant has been reported in numerous ARVC
cohorts.
The revised ARVC task force score was calculated for
each gene-positive patient (2). “Deﬁnite” diagnoses of
ARVC were present in 3 patients; the remainder were either
“borderline” (n ¼ 9) or “possible” diagnoses (n ¼ 18). We
also summarized the burden of disease in our cohort by
calculating the task force score excluding section VI (“family
history”). Twenty-four of 30 subjects (80%) were now
considered “negative” for ARVC (i.e., lacking a recognized
phenotype of the disease) (Table 1).
Resting ECG abnormalities. By study design, no asymp-
tomatic gene carrier had a major ECG criterion for the
diagnosis of ARVC. On analysis, no healthy control had
a major criterion for ARVC on resting electrocardiography.
However, 1 of 30 (3%) healthy controls had TAD  55 ms
(a minor criterion in the TFC) on resting electrocardiog-
raphy. This ﬁnding was present in 6 of 28 (21%) asymp-
tomatic gene carriers (p ¼ 0.05; 2 had resting right bundle
branch block [RBBB] and were excluded from this analysis).
No subject in either group had TWI reaching minor crite-
rion status.
In asymptomatic gene carriers, signal-averaged ECG
results were positive in at least 1 of 3 criteria in 9 of 25 (36%)
(Table 2). Although signal-averaged electrocardiography
was not performed in healthy subjects, the largest study to
date examining the utility of signal-averaged ECG criteria
for the diagnosis of ARVC reported speciﬁcity of 92%
for 1 of 3 criteria (5).
Table 1 Clinical Characteristics and Exercise Results of Asymptomatic ARVC Gene Carriers
Patient
#
Age
(yrs) Sex
2010
TFC
Modiﬁed
2010 TFC
MRI
Results
Holter
PVCs SAECG
Affected
Gene(s) Coding
Protein
Product
New
Epsilon
Waves
Superior-
Axis PVCs
Inferior-
Axis PVCs
TAD
55 ms
TWI
Beyond
Lead V2
STE
0.1 mV
1 18 F Possible Negative Normal 0 0 PKP2 c.1613G>A Trp538X N N N N N N
2 42 F Possible Negative Normal 48 0 PKP2 c.1912C>T Gln638X N N Y N Y N
3 67 M Possible Negative Normal 36 NA PKP2 c.1912C>T Gln638X N Y Y N N N
4 59 F Possible Negative Normal 10 0 PKP2 c.1613G>A Trp538X N N N N N N
5 24 F Possible Negative Normal 93 0 PKP2 c.1912C>T Gln638X N N N N Y N
6 17 F Possible Negative Normal 0 0 PKP2 c.1912C>T Gln638X N N Y Y N Y
7 19 M Possible Negative Normal 0 Q PKP2 c.1912C>T Gln638X Y N N Y N N
8 48 F Deﬁnite Possible Normal 1,469 Q, R TMEM43 c.1073C>T Ser358Leu N Y N Y N N
9 53 M Borderline Possible Normal 1,526 Q, H, R PKP2 c.1912C>T Gln638X Y N Y Y N N
10 59 F Possible Negative Normal 38 0 PKP2 c.1912C>T Gln638X N N Y N N N
11 21 M Borderline Possible Normal{ 4 Q PKP2 c.1912C>T Gln638X Y Y N d N N
12 28 F Possible Negative Normal 0 0 PKP2,
DSG2
c.1580T>C,
c.3061_3062delAG
Leu527Pro,
Ser1021X
N N Y N N N
13 69 M Borderline Negative Normal{ 258 H, R PKP2,
DSG2
c.2431C>A,
c.1439C>T
Arg811Ser,
Thr480Ile
N Yjj N d Y N
14 59 F Borderline Negative Normal 1,689jj 0 DSG2 c.166G>A Val56Met N Y Y Y N N
15 31 M Borderline Possible Minor 15 Qy PKP2 c.2197_2202delinsG His733fsX740 N N N d N N
16 56 F Borderline Negative Normal 0 R PKP2 c.2197_2202delinsG His733fsX740 N N Y N N N
17 73 M Borderline Negative Normal 181 H, R PKP2 c.2197_2202delinsG His733fsX740 N N N N N N
18 24 F Possible Negative Normal 11 0 PKP2 c.2197_2202delinsG His733fsX740 N N N N Y N
19 66 M Deﬁnite Deﬁnite Major{ 713 Q, H, Ry PKP2 c.2146_1G>C Mutant splice
product
Y N Y d Y N
20 48 F Deﬁnite Possible Normal 9 0 PKP2 c.2216_2217delAT His739fs N N Y Y Y N
21 34 F Possible Negative Normal 71 0 TMEM43 c31073C>T Ser358Leu N N N d N N
22 37 F Borderline Negative Normal 1,268 H PKP2 c.2216_2217delAT His739fs N N Y N N N
23 43 F Possible Negative Normal 11 0 PKP2 c.2216_2217delAT His739fs N N Y N N N
24 50 M Possible Negative Normal 10 Q, H, Ry PKP2 c.1378þ1G>C Mutant splice
product
x Y N x N N
25 17 M Possible Negative Normal 0 0 PKP2 c.148_151delACAG Ser50fsX110 N N N N N N
26 55 M Possible Negative Normal 184 0 PKP2 c.1643delG Val548X N Y Y N N N
27 14 M Possible Negative Normal 1 0 PKP2 c.148_151delACAG Ser50fsX110 N N N N N N
28 20 M Possible Negative Normal NA 0 PKP2 c.1643delG Val548fsX562 Y N N d N N
29 19 M Possible Negative Normal 4 Q, H, Ry PKP2 c.2484C>Tz Mutant splice
product
x N N x N N
30 21 M Borderline Negative Normal 420 Q, L PKP2 c.235C>T Arg79X N N N Y N N
A modiﬁed 2010 TFC score was calculated, excluding section VI (family history), to more accurately summarize the burden of structural and electrical disease. A dash indicates that the abnormality was present on resting electrocardiography. *Axis could not be determined.
yBaseline QRS duration 110 ms, therefore the results of SAECG were not interpretable (2010 TFC) (2). zHomozygous for mutation. xRight bundle branch block at baseline, therefore TAD was not interpretable (2010 TFC) (2). jjNonsustained ventricular tachycardia.
{Transthoracic echocardiography.
ARVC ¼ arrhythmogenic right ventricular cardiomyopathy; DSG2 ¼ desmoglein 2; H ¼ low-amplitude signal duration 38 ms; MRI ¼ magnetic resonance imaging; N ¼ no; NA ¼ not available; PKP2 ¼ plakophilin-2; PVC ¼ premature ventricular contraction; Q ¼ ﬁltered
QRS 114 ms); R ¼ root mean square voltage of terminal 40 ms 20 mV; SAECG¼ signal-averaged electrocardiography; STE ¼ ST-segment elevation; TAD ¼ terminal activation duration; TFC¼ task force criteria; TMEM43 ¼ transmembrane protein 43; TWI¼ T-wave inversion;
Y ¼ yes.
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Table 2 Summary Data Comparing Asymptomatic Gene Carriers With Healthy Control Patients
Variable
Asymptomatic ARVC Gene Carriers
(n ¼ 30)
Healthy Controls
(n ¼ 30) p Value
Age (yrs) 39.7  18.9 38.4  10.7 0.80
Men 15 15 1.00
Resting electrical abnormalities
TWI in leads V1 and V2 0 (0%) 0 (0%) 1.00
TAD 55 ms 6/28 (21%) 1 (3%) 0.05
SAECG (1 criterion) 9/25 (36%) d d
Exercise-induced depolarization abnormalities
Epsilon wave 4/28 (14%) 0 (0%) 0.048
PVCs
Any 17 (57%) 3 (10%) 0.0003
Superior axis 7 (23%) 0 (0%) 0.01
TAD 55 ms 7/22 (31%) 2/29 (7%) 0.03
Exercise-induced repolarization abnormalities
TWI beyond lead V2 6/28 (21%) 4 (13%) 0.50
ST-segment elevation 0.1 mV 2 (7%) 2 (7%) 1.00
Values are mean  SD, n, n (%), or n/N (%). When the denominator is <30, the abnormality was present at rest or else could not be assessed (e.g.,
resting QRS must be <110 ms to interpret the results of SAECG; see the Methods section).
Abbreviations as in Table 1.
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1775New abnormalities of depolarization during ETT.
EPSILON WAVES AND NEW PROLONGATION OF QRS TAD. Two
asymptomatic gene carriers were excluded from the anal-
ysis of epsilon waves because of the presence of resting
RBBB. In the remaining cohort, new epsilon waves
appeared during ETT in 4 of 28 (14%) (Fig. 1).
No healthy controls developed new epsilon waves (0 of 30
p ¼ 0.048).
Resting QRS TAD 55 ms was present in 6 of 28 (21%)
asymptomatic ARVC gene carriers (excluding 2 patients
with RBBB). In the remaining subjects, 7 of 22 (32%)
developed TAD 55 ms during ETT. In each case,
TAD 55 ms was present during the recovery period.
Resting TAD 55 ms was present in 1 healthy control andFigure 1 Epsilon Waves Appearing During Exercise
(A) An epsilon wave appeared during early exercise in subject #9 and persisted during the
(arrows) was prominent late into the recovery period. Both asymptomatic subjects had n
resonance imaging and harbored radical plakophilin 2 mutations.developed during exercise in another 2 of 29 (p ¼ 0.03 vs.
asymptomatic gene carriers).
PVCS. PVCs of any conﬁguration were recorded during
ETT in 17 of 30 (57%) asymptomatic gene carriers and 3 of
30 (10%) healthy controls (p ¼ 0.0003). Superior-axis PVCs
were seen in 7 of 30 (23%) asymptomatic gene carriers and
were not observed in healthy controls (p ¼ 0.01).
In 2 gene carriers, nonsustained ventricular tachycardia
was noted during ETT: superior axis in 1 and inferior axis in
the other. Nonsustained ventricular tachycardia was not
recorded in healthy controls. Sustained ventricular tachy-
cardia was not seen in either group.
Thus, among exercise-induced abnormalities of depolar-
ization, new epsilon waves, new QRS TAD 55 ms, andrecovery period (arrows). (B) In subject #7, a relatively large amplitude epsilon wave
ormal results on rest electrocardiography and normal results on cardiac magnetic
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1776ventricular ectopic activity occurred with greater frequency in
asymptomatic ARVC gene carriers. In addition, superior-axis
PVCs were unique to asymptomatic ARVC gene carriers.
New abnormalities of repolarization during ETT.
ST-SEGMENT ELEVATION. New ST-segment elevation 1
mV in the right precordial leads was noted in 2 of 30 (7%)
asymptomatic gene carriers and 2 of 30 (7%) healthy
controls (p ¼ 1.00).
NEW TWI. TWI extending to lead V3 or beyond developed
in 6 of 28 gene carriers (21%; 2 had resting RBBB).
However, 4 of 30 healthy controls (13%) developed TWI to
lead V3 or beyond (p ¼ 0.50). TWI typically developed early
in exercise and resolved at peak exercise in both groups.
Thus, both abnormalities of repolarization occurred with
equal frequency between asymptomatic ARVC gene carriers
and healthy controls.
Phase 2 study: ETT in TFC-positive patients with
ARVC with histories of sustained ventricular tachycardia
or cardiac arrest. BASELINE CHARACTERISTICS. The mean
age of the symptomatic ARVC cohort was 40.7  10.9
years, and 18 of 25 (72%) were men. In this phase, the ETT
results of an additional 17 asymptomatic ARVC gene
carriers were evaluated, for a total of 47 patients. The mean
age of these 47 patients was 36.6  18.1 years, and 18 of
47(38%) were men.
We applied modiﬁed TFC for the diagnosis of familial
ARVC to this expanded asymptomatic gene carrier cohort
(Online Table 2). These criteria, proposed by Hamid et al.
(6), consider minor electrical and structural abnormalities
identiﬁed in ﬁrst-degree relatives of an ARVC proband as
signs of early disease. We modiﬁed the original criteria of
Hamid et al. to accommodate the now widespread avail-
ability of cardiac magnetic resonance imaging and deﬁned
“minor” abnormalities according to the minor ARVC
criteria of the 2010 TFC (2). Consistent with Hamid et al.,
we also considered a PVC count >200 in 24 h as a sign of
disease. In our asymptomatic cohort, only 21 of 47 (45%)
were considered to have ARVC by the modiﬁed criteria of
Hamid et al. Of note, 5 of the remaining 26 patients
negative per the criteria of Hamid et al. had either superior-
axis PVCs or new epsilon waves during exercise, suggesting
incremental value to exercise-induced changes in identifying
affected ﬁrst-degree relatives. Including these exercise
changes would increase the sensitivity of the modiﬁed
criteria to 55% (26 of 47).
In addition, we evaluated the ETT results of a further 40
healthy controls, for a total of 70 healthy subjects. The
additional healthy subjects were all gene-negative, ﬁrst-
degree relatives of probands diagnosed at an inherited
arrhythmia clinic. The mean age of this expanded cohort was
35.8  15.2 years, and 28 of 70 (40%) were men.
Resting ECG abnormalities. Major criteria for ARVC
were present on resting electrocardiography in 12 of 25
(48%) patients with symptomatic ARVC. Resting epsilon
waves and TWI reaching lead V3 were present in 6 and 9patients, respectively. Both abnormalities were present in
3 patients. By study design, no asymptomatic gene carrier
had a major ECG criterion on resting electrocardiography.
Minor criteria were present, however, in 11 of 47 (23%)
asymptomatic ARVC gene carriers, consisting of QRS
TAD 55 ms in 8 subjects and minor TWI criterion in
3 subjects.
New abnormalities of depolarization during ETT. Dur-
ing ETT, new epsilon waves appeared in 6 of 45 asymp-
tomatic gene carriers (13%) and 3 of 18 subjects with
symptomatic ARVC (17%). PVCs of any axis were recorded
in 27 of 47 asymptomatic ARVC gene carriers (57%) and 23
of 25 patients with symptomatic ARVC (92%). Superior-
axis PVCs were recorded in 10 of 47 asymptomatic gene
carriers (21%) and 21 of 25 patients with symptomatic
ARVC (84%) (Fig. 2).
In patients with symptomatic ARVC, the predominant
conﬁguration of superior-axis PVCs was left bundle branch
block, identiﬁed in 17 of 21 subjects. The remaining 4
subjects had superior-axis PVCs of indeterminate conﬁgu-
ration (PVCs not recorded in leads V1 and V2). Four symp-
tomatic patients showed both RBBB and left bundle branch
block superior-axis PVCs. In asymptomatic gene carriers, 9 of
10 displayed left bundle branch block or indeterminate-
conﬁguration superior-axis PVC conﬁgurations. RBBB
conﬁguration was also seen in 4 subjects and was the only
conﬁguration of superior-axis PVC in a single subject.
Overall, in the expanded healthy control cohort, 11 of 70
(16%) developed PVCs during ETT. One of the 70 (1.4%),
a 63-year-old woman, developed superior-axis PVCs; the
bundle branch conﬁguration could not be determined. New
epsilon waves were not seen in any healthy control (0 of 70).
Last, new prolonged QRS TAD 55 ms developed in 11
of 36 asymptomatic ARVC gene carriers (31%) and 8 of 12
patients with symptomatic ARVC patients (67%) (p¼ 0.04).
Thus, abnormalities seen in a proportion of asymptomatic
ARVC gene carriers during ETT were also seen, albeit at
a higher frequency, in patients with symptomatic ARVC
with histories of sustained ventricular arrhythmia or cardiac
arrest. These results are summarized in Table 3.
Discussion
The principal ﬁnding of this study is that exercise testing
may expose a latent electrical substrate of ARVC in
asymptomatic gene carriers that is absent from healthy
subjects but shared by patients with symptomatic ARVC
and histories of ventricular arrhythmia or cardiac arrest. Two
abnormalities found in asymptomatic ARVC gene carriers,
epsilon waves and superior-axis PVCs, were rare or absent in
healthy controls. Furthermore, new epsilon waves and/or
superior-axis PVCs appeared during ETT in 22 of 25
patients with ARVC (88%) with histories of sustained
ventricular arrhythmia and/or cardiac arrest, indicating that
these observations may be clinical markers of greater
arrhythmic risk.
Figure 2 PVCs During Exercise Treadmill Testing
Electrocardiogram recorded during the recovery period of an exercise treadmill test in a 41-year-old man with arrhythmogenic right ventricular cardiomyopathy and a history of
sustained ventricular arrhythmia. This patient was found to have a large deletion of plakophilin 2. A short triplet of premature ventricular contractions (PVCs) was recorded with
an inferior (outﬂow tract–like) conﬁguration. A single superior-axis PVC was noted later in the recording. PVCs were not seen at rest or during the exercise stage of the test.
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1777A small number of studies have examined the effects of
exercise in ARVC. Toyofuku et al. (7) evaluated 17 ARVC
probands with histories of sustained ventricular tachycardia.
During ETT, ST-segment elevation 0.1 mV developed in
11 of 17 (65%). Although not a focus of their study,
ventricular ectopic activity and/or ventricular arrhythmia was
noted in 14 of 17 (82%); this occurred despite a high rate of
antiarrhythmic medication. Sequeira et al. (8) assessed ETT
observations in a small study of 16 patients (age <18 years)
with ARVC. The pattern and inducibility of ventricular
ectopic activity were found to be variable. Consequently, the
investigators urged caution in using ETT to rule in or out
a diagnosis of ARVC. However, in contrast to our study,
their patients were much younger, the proportion of patients
with histories of sustained ventricular arrhythmia was not
reported, and more than 50% of the treadmill tests were
performed while on antiarrhythmic medications. Last,
Furlanello et al. (9) studied 32 athletes with ARVC,
including 20 with histories of sustained ventricular tachy-
cardia. In the entire cohort, bicycle exercise–induced vent-
ricular ectopic activity or tachycardia occurred in 69%. The
correlation between exercise results and a history of sus-
tained ventricular arrhythmia was not reported.
In this limited body of research, our study is unique for
enrolling asymptomatic ARVC gene carriers. Consequently,
manifest structural disease of the right ventricle was rare in
our cohort: 2 of 47 met minor or major 2010 TFC.
Furthermore, by study design, all subjects did not have major
ECG criteria for ARVC. The small burden of disease in our
cohort may be summarized by calculating a modiﬁed TFC
2010 score excluding genotype and family history. By thismethod, 40 of 47 (85%) were considered “negative” for
ARVC (i.e., showing no or little manifestation of the
disease). The low burden of disease identiﬁed in ARVC
gene carriers identiﬁed through cascade family screening
demonstrates that genetic defects do not in themselves
constitute disease but are markers of risk. It is now common
to identify genotype-positive relatives of a proband, both
young and old, with active lifestyles and no overt manifes-
tation of the disease. In our asymptomatic cohort, 11 of 47
were >50 years of age, but only 1 displayed overt structural
cardiac disease. Given the low penetrance of symptomatic
and overt structural disease in genotype-positive family
members, the question arises as to how asymptomatic gene
carriers should be managed; speciﬁcally, is it possible to risk-
stratify who may be at higher risk for ventricular arrhythmia
or sudden cardiac death?
Our symptomatic ARVC cohort exposes the problem of
arrhythmia risk prediction on the basis of baseline testing
performed at rest. Despite histories of sustained ventricular
arrhythmia or aborted cardiac arrest, 9 of 25 (36%) did not
have major or minor criteria for right ventricular disease on
cardiac imaging, 13 of 25 (52%) had no major ECG criteria,
and 6 of 25 (24%) had both normal cardiac imaging and no
major ECG criteria. That is, a signiﬁcant proportion did not
have apparent structural or electrical phenotypes that would
be predicted to predispose to their arrhythmia. In contrast,
the response to exercise was signiﬁcant: 22 of 25 (88%)
developed superior-axis PVCs and/or new epsilon waves
during exercise. The remaining 3 had resting epsilon waves.
These same exercise abnormalities were identiﬁed in a subset
of asymptomatic gene carriers: 15 of 47 (32%) developed
Table 3 Summary Data Comparing Asymptomatic Gene Carriers With Patients With Symptomatic (VT) ARVC
Variable
Healthy Controls
(n ¼ 70)
Asymptomatic ARVC
Gene Carriers
(n ¼ 47)
Patients With
Symptomatic ARVC
(n ¼ 25)
p Value
(Controls vs.
Asymptomatic
Gene Carriers)
p Value
(Asymptomatic Gene
Carriers vs. Patients With
Symptomatic ARVC)
Age (yrs) 35.8  15.2 36.7  18.1 40.7  10.9 0.78 0.24
Men 28 (40%) 18 (38%) 18 (72%) 1.00 0.01
Genotype
PKP2 d 43 (91%) 19 (76%) d 0.09
Structural RV abnormalities
Major criterion d 1 (2%) 16 (64%) d <0.0001
Minor criterion d 1 (2%) 0 (0%) d 1.00
Resting ECG abnormalities
TWI in leads V1 to V3 0/70 0/45 (0%) 9 (36%) 1.00 <0.0001*
Epsilon waves 0/70 0/45 (0%) 6 (24%) 1.00 0.002*
TAD 55 ms d 10/45 (22%) 11/24 (45) d 0.06
SAECG (1 criterion) d 10/41 (24%) 17/21 (81) d <0.0001
Exercise ECG abnormalities
Epsilon waves 0/70 6/45 (13%) 3/18 (17%) 0.003 0.70
PVCs
Any 11/70 (11%) 27 (57%) 23 (92%) <0.0001 0.003
Superior axis 1/70 (1%) 10 (21%) 21 (84%) 0.0004 <0.0001
TAD  55 ms d 11/36 (31%) 8/12 (67%) d 0.04
Values are mean  SD, n (%), or n/N (%). Where the denominator is <47 (asymptomatic gene carriers) or 25 (patients with symptomatic ARVC), the abnormality was present at rest or else could not be
assessed (see the Methods section). *By study design, no subjects with resting major ECG criteria for ARVC were enrolled into the asymptomatic gene carrier cohort.
ECG ¼ electrocardiographic; RV ¼ right ventricular; other abbreviations as in Table 1.
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1778superior-axis PVCs and/or new epsilon waves. Given
a shared exercise phenotype between asymptomatic gene
carriers and patients with symptomatic ARVC, we would
suggest that asymptomatic patients showing these abnor-
malities are in transition to a stage of disease associated with
a higher risk for ventricular arrhythmia. Speciﬁc cases from
our cohort and the published research illustrate this concept.
A 36-year-old male patient in our symptomatic cohort was
initially diagnosed with benign syncope on the basis of
clinical history, normal cardiac imaging results, and normal
results on resting electrocardiography. Over the following
year, the patient developed intractable ventricular arrhythmia
and was diagnosed with ARVC on the basis of the 2010
TFC. Analysis of ETT results at initial evaluation revealed
isolated superior-axis PVCs. Similarly, Sanatani et al. (10)
described the case of an male adolescent who experienced
sudden cardiac death during exercise and was diagnosed
with ARVC at autopsy. Three years previously, he had
received a diagnosis of benign syncope after normal inves-
tigations. However, retrospective analysis of his ETT results
at initial evaluation revealed a single superior-axis PVC.
The management of asymptomatic ARVC gene carriers
is uncertain. Current practice involves lifelong clinical
assessment but at ill-deﬁned time intervals and with no
speciﬁc recommendations as to when any speciﬁc therapies
might be considered. Furthermore, the issue of exercise
restriction is challenging in asymptomatic gene carriers
without symptoms or overt clinical disease. The European
Society of Cardiology recommends against all competitive
sports in ARVC gene carriers without clinical phenotypesof disease (11). The distinction between competitive and
recreational sports is not clear in our minds; many subjects
exert to high intensity even during “noncompetitive” sports.
In contrast, the 36th Bethesda Conference allows partici-
pation in all sports when a phenotype of disease is absent
(11). The psychological consequences of receiving a
life-changing diagnosis coupled with major lifestyle
changes should be considered. In our view, risk should be
individualized on the basis of the burden of disease in
an individual patient (structural disease, PVCs on Holter
monitoring, and so on), with particular attention to
exercise-induced abnormalities. Patients showing ventric-
ular ectopic activity, especially of superior axis morphology,
would be advised to avoid exercise intensity to a greater
extent than other asymptomatic gene carriers with consis-
tently normal treadmill exercise results. Consideration
might be given to beta-blocker therapy or to speciﬁc heart
rate limits during exercise to attenuate risk, rather than
complete cessation of all activity. Although from our
perspective, exercise prescription should be based on an
assessment of the burden of disease in an individual patient,
we would advise against high-intensity endurance exercise
in all gene carriers, as animal models of ARVC suggest that
endurance exercise may speed the development of the
ARVC phenotype (12).
In addition to risk stratiﬁcation in asymptomatic gene
carriers, we can envisage several novel uses of ETT in the
evaluation of suspected ARVC that will require validation
in future studies. The demonstration of epsilon waves
appearing during exercise is novel to our knowledge and
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1779apparently infrequent, being absent from healthy controls.
It is therefore a possible candidate to be included in future
revisions of TFC. ETT may also be useful when screening
the asymptomatic relatives of an ARVC proband when
initial testing does not reveal a genetic cause. Further-
more, genetic testing is not routinely available in many
countries or is prohibitively expensive. ETT, with other
noninvasive modalities, may be used to identify a pheno-
type of disease in asymptomatic relatives. Exercise
prescription could then be provided on the basis of the
results of this testing.
Study limitations. Overall, about 90% of asymptomatic
gene carriers in our study had PKP2 mutations. The
generalization of our ﬁndings to other genotypes may
therefore be brought into question. The high rate of PKP2
mutations resulted from an enrollment bias that all muta-
tions be deﬁnitely pathogenic.
We did not demonstrate the reproducibility of ETT
results in our patients. It is possible that ectopic activity and
other abnormalities may be present in a higher proportion of
subjects when serial testing is performed.
The reproducibility of TAD measurements was recently
brought into question by Jain et al. (13). We found this
measurement difﬁcult and agree that its diagnostic useful-
ness is likely to be low in the absence of true blinding.
Importantly, our discussion and conclusion do not rest on
TAD but rather the appreciation of exercise-induced epsilon
waves and ventricular ectopic activity.
We would advise caution in the application of our ﬁnd-
ings to large populations in which the pretest probability of
ARVC is likely to be low, such as healthy athletes. Even
uncommon exercise abnormalities such as superior-axis
PVCs are more likely to be “normal” when the population
incidence of ARVC is low (14).
Perhaps the most signiﬁcant weakness of our study is
the lack of long-term follow-up. A shared exercise phe-
notype between asymptomatic gene carriers and patients
with symptomatic ARVC is suggestive of a vulnerability to
arrhythmia in these patients; however, a deﬁnitive answer as
to how vulnerable such patients are cannot be made at this
time.
Conclusions
We performed ETT in asymptomatic ARVC gene carriers,
age-matched and sex-matched healthy controls, and a cohort
of patients with symptomatic (ventricular arrhythmia or
cardiac arrest) ARVC. Our principal ﬁnding is that exercise
can expose an electrical phenotype in asymptomatic ARVC
gene carriers that is absent from healthy controls but shared
by patients with manifest and symptomatic ARVC. In
asymptomatic ARVC gene carriers, the results of exercise
testing may be useful to identify a developing substrate ofARVC and thus prioritize medical surveillance and guide
exercise prescription.
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APPENDIX
For an expanded methods section and supplemental tables, please see the
online version of this article.
